Polyphor Ltd. - Product Pipeline Review - 2015

Date: April 30, 2015
Pages: 40
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: P4A9CC80F0CEN
Leaflet:

Download PDF Leaflet

Summary

Global Markets Direct’s, ‘Polyphor Ltd. - Product Pipeline Review - 2015’, provides an overview of the Polyphor Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Polyphor Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Polyphor Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Polyphor Ltd.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Polyphor Ltd.’s pipeline products
Reasons to buy
  • Evaluate Polyphor Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Polyphor Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Polyphor Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Polyphor Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Polyphor Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Polyphor Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
Polyphor Ltd. Snapshot
Polyphor Ltd. Overview
Key Information
Key Facts
Polyphor Ltd. - Research and Development Overview
Key Therapeutic Areas
Polyphor Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Polyphor Ltd. - Pipeline Products Glance
Polyphor Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Polyphor Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Polyphor Ltd. - Drug Profiles
POL-6326
Product Description
Mechanism of Action
R&D Progress
POL-5551
Product Description
Mechanism of Action
R&D Progress
POL-6014
Product Description
Mechanism of Action
R&D Progress
POL-6926
Product Description
Mechanism of Action
R&D Progress
POL-7080 Follow-On
Product Description
Mechanism of Action
R&D Progress
POL-7085
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Infectious Diseases
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Agonize FPR1/2 for Infectious Disease and Immunology
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Antagonize FPR1/2 for Infectious Disease and Immunology
Product Description
Mechanism of Action
R&D Progress
Polyphor Ltd. - Pipeline Analysis
Polyphor Ltd. - Pipeline Products by Target
Polyphor Ltd. - Pipeline Products by Route of Administration
Polyphor Ltd. - Pipeline Products by Molecule Type
Polyphor Ltd. - Pipeline Products by Mechanism of Action
Polyphor Ltd. - Recent Pipeline Updates
Polyphor Ltd. - Dormant Projects
Polyphor Ltd. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Polyphor Ltd., Key Information
Polyphor Ltd., Key Facts
Polyphor Ltd. - Pipeline by Indication, 2015
Polyphor Ltd. - Pipeline by Stage of Development, 2015
Polyphor Ltd. - Monotherapy Products in Pipeline, 2015
Polyphor Ltd. - Partnered Products in Pipeline, 2015
Polyphor Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
Polyphor Ltd. - Out-Licensed Products in Pipeline, 2015
Polyphor Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Polyphor Ltd. - Phase II, 2015
Polyphor Ltd. - Phase I, 2015
Polyphor Ltd. - Preclinical, 2015
Polyphor Ltd. - Discovery, 2015
Polyphor Ltd. - Pipeline by Target, 2015
Polyphor Ltd. - Pipeline by Route of Administration, 2015
Polyphor Ltd. - Pipeline by Molecule Type, 2015
Polyphor Ltd. - Pipeline Products by Mechanism of Action, 2015
Polyphor Ltd. - Recent Pipeline Updates, 2015
Polyphor Ltd. - Dormant Developmental Projects,2015

LIST OF FIGURES

Polyphor Ltd. - Pipeline by Top 10 Indication, 2015
Polyphor Ltd. - Pipeline by Stage of Development, 2015
Polyphor Ltd. - Monotherapy Products in Pipeline, 2015
Polyphor Ltd. - Pipeline by Top 10 Target, 2015
Polyphor Ltd. - Pipeline by Top 10 Route of Administration, 2015
Polyphor Ltd. - Pipeline by Top 10 Molecule Type, 2015
Polyphor Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Allergic Conjunctivitis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 71 pages

Ask Your Question

Polyphor Ltd. - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: